Passage Bio, Inc. (PASG)
NASDAQ: PASG · Real-Time Price · USD
4.750
+0.260 (5.79%)
Aug 4, 2026, 2:48 PM EDT - Market open
Passage Bio Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 33.34 | 46.3 | 37.57 | 21.71 | 34.6 | 128.97 |
Short-Term Investments | - | - | 39.18 | 92.59 | 155.01 | 186.81 |
Cash & Short-Term Investments | 33.34 | 46.3 | 76.76 | 114.29 | 189.61 | 315.77 |
Cash Growth | -47.38% | -39.67% | -32.84% | -39.72% | -39.95% | 3.59% |
Other Current Assets | 1.41 | 1.46 | 2.06 | 3.67 | 7.43 | 9.29 |
Total Current Assets | 34.74 | 47.76 | 78.82 | 117.96 | 197.04 | 325.07 |
Net Property, Plant & Equipment | 1.48 | 14.28 | 23.13 | 32.15 | 42.24 | 23.81 |
Other Long-Term Assets | 0.24 | 0.24 | 0.46 | 0.43 | 4.27 | 6.2 |
Total Assets | 36.46 | 62.28 | 102.41 | 150.55 | 243.55 | 355.08 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.31 | 1.11 | 0.74 | 1.3 | 4.07 | 9.45 |
Accrued Expenses | 3.9 | 4.65 | 6.71 | 11.67 | 11.01 | 20.05 |
Current Portion of Leases | 1.15 | 3.57 | 3.69 | 3.37 | 3.28 | - |
Unearned Revenue | 13.75 | 13.75 | 8.23 | - | - | - |
Total Current Liabilities | 20.1 | 23.08 | 19.36 | 16.34 | 18.35 | 29.5 |
Long-Term Leases | 4.61 | 20.44 | 21.79 | 22.92 | 23.83 | - |
Other Long-Term Liabilities | - | - | - | - | - | 6.92 |
Total Long-Term Liabilities | 4.61 | 20.44 | 21.79 | 22.92 | 23.83 | 6.92 |
Total Liabilities | 24.71 | 43.53 | 41.15 | 39.26 | 42.18 | 36.42 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | - | - | - | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 724.07 | 723.51 | 720.49 | 705.79 | 694.73 | 675.35 |
Accumulated Other Comprehensive Income | - | 0.01 | - | -0.04 | -0.97 | -0.41 |
Retained Earnings | -712.32 | -704.76 | -659.24 | -594.47 | -492.41 | -356.28 |
Shareholders' Equity | 11.75 | 18.76 | 61.25 | 111.28 | 201.37 | 318.66 |
Total Liabilities & Equity | 36.46 | 62.29 | 102.4 | 150.55 | 243.55 | 355.08 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 5.76 | 24.01 | 25.48 | 26.29 | 27.11 | 0 |
Net Cash (Debt) | 27.58 | 22.29 | 51.28 | 88 | 162.5 | 315.77 |
Net Cash Growth | -27.88% | -56.53% | -41.73% | -45.85% | -48.54% | 3.59% |
Net Cash Per Share | 8.66 | 7.03 | 16.66 | 32.15 | 59.71 | 118.39 |
Book Value | 11.75 | 18.76 | 61.25 | 111.28 | 201.37 | 318.66 |
Book Value Per Share | 3.69 | 5.91 | 19.90 | 40.66 | 73.99 | 119.47 |
Tangible Book Value | 11.75 | 18.76 | 61.25 | 111.28 | 201.37 | 318.66 |
Tangible Book Value Per Share | 3.69 | 5.91 | 19.90 | 40.66 | 73.99 | 119.47 |